Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriano Lazzarin

Showing results (141-150 of 288) with videos related to

Pageof 29
Sort By:
The New Microbiologica|January 5, 2007
Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patientsHamid Hasson, Priscilla Biswas, Laura Galli, et al.
The New Microbiologica|October 31, 2012
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study)Hamid Hasson, Laura Galli, Giulia Gallotta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 19, 2018
Diagnostic and Prognostic Value of JC Virus DNA in Plasma in Progressive Multifocal LeukoencephalopathyFrancesca Ferretti, Arabella Bestetti, Constantin T Yiannoutsos, et al.
The New Microbiologica|May 18, 2017
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016Andrea Antinori, Antonio Di Biagio, Simone Marcotullio, et al.
AIDS (London, England)|October 4, 2008
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort studyAlessandro Cozzi-Lepri, Andrew N Phillips, Bonaventura Clotet, et al.
Journal of the International AIDS Society|November 14, 2014
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGOJean-Michel Molina, Bonaventura Clotet, Jan van Lunzen, et al.
Open Forum Infectious Diseases|January 12, 2019
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIVVincenzo Spagnuolo, Andrea Poli, Laura Galli, et al.
International Journal of Antimicrobial Agents|January 12, 2020
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patientsNadia Galizzi, Andrea Poli, Laura Galli, et al.
AIDS (London, England)|July 16, 2019
Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppressionRaffaele Dell'Acqua, Laura Galli, Andrea Poli, et al.
AIDS Research and Human Retroviruses|May 23, 2002
Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2Claudio Fortis, Laura Soldini, Silvia Ghezzi, et al.
Pageof 29

Showing results (141-150 of 288) with videos related to

Sort By:
Pageof 29
The New Microbiologica|January 5, 2007
Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patientsHamid Hasson, Priscilla Biswas, Laura Galli, et al.
The New Microbiologica|October 31, 2012
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study)Hamid Hasson, Laura Galli, Giulia Gallotta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 19, 2018
Diagnostic and Prognostic Value of JC Virus DNA in Plasma in Progressive Multifocal LeukoencephalopathyFrancesca Ferretti, Arabella Bestetti, Constantin T Yiannoutsos, et al.
The New Microbiologica|May 18, 2017
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016Andrea Antinori, Antonio Di Biagio, Simone Marcotullio, et al.
AIDS (London, England)|October 4, 2008
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort studyAlessandro Cozzi-Lepri, Andrew N Phillips, Bonaventura Clotet, et al.
Journal of the International AIDS Society|November 14, 2014
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGOJean-Michel Molina, Bonaventura Clotet, Jan van Lunzen, et al.
Open Forum Infectious Diseases|January 12, 2019
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIVVincenzo Spagnuolo, Andrea Poli, Laura Galli, et al.
International Journal of Antimicrobial Agents|January 12, 2020
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patientsNadia Galizzi, Andrea Poli, Laura Galli, et al.
AIDS (London, England)|July 16, 2019
Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppressionRaffaele Dell'Acqua, Laura Galli, Andrea Poli, et al.
AIDS Research and Human Retroviruses|May 23, 2002
Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2Claudio Fortis, Laura Soldini, Silvia Ghezzi, et al.
Pageof 29